We are validating our patented cold plasma device for breast conserving surgery, which suffers from a 15% recurrence leading to mastectomy.
NexPlasmaGen was founded in Montreal by Dr Léveilé. It has 5 shareholders including McGill University. Dr. Léveillé has invented a cold plasma technology with the potential to selectively kill cancer cells remaining at the tissue margin after cancer surgery. This technology has applications across different cancers. Our business model is to partner with cancer treatment device manufacturers to leverage their distribution channels.